AstraZeneca addresses report that CEO Pascal Soriot plans to depart

Nicole DeFeudis

Editor

AstraZeneca brushed off a news report that longtime CEO Pascal Soriot plans to leave the company.

British tabloid The Daily Mail on Sunday had reported that the 64-year-old chief may depart as soon as next year, citing an unnamed source. AstraZeneca’s stock was down more than 2% on Monday afternoon, trading at about $67 per share.

An AstraZeneca spokesperson told Endpoints News via email that the company doesn’t “comment on market rumors.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

AstraZeneca addresses report that CEO Pascal Soriot plans to depart

Nicole DeFeudis

Editor

Unlock this article instantly by becoming a free subscriber.

‘A new era of growth’: AstraZeneca aims for $80B revenue, 20 new drugs by 2030

Exclusive: Members of Congress buy and sell stocks that would gain from bill banning China biotech companies

Dyne Therapeutics sharpens case for two muscle disease therapies with updated data

FDA approves first two interchangeable biosimilars to Regeneron's blockbuster Eylea

FDA withdraws Helsinn’s accelerated approval for cancer drug after company’s request

Back to the future: From target-selective drug design to AI-enabled polypharmacology

As­traZeneca ad­dress­es re­port that CEO Pas­cal So­ri­ot plans to de­part

Nicole DeFeudis

Editor

Unlock this article instantly by becoming a free subscriber.

‘A new era of growth’: As­traZeneca aims for $80B rev­enue, 20 new drugs by 2030

Ex­clu­sive: Mem­bers of Con­gress buy and sell stocks that would gain from bill ban­ning Chi­na biotech com­pa­nies

Dyne Ther­a­peu­tics sharp­ens case for two mus­cle dis­ease ther­a­pies with up­dat­ed da­ta

FDA ap­proves first two in­ter­change­able biosim­i­lars to Re­gen­eron's block­buster Eylea

FDA with­draws Helsinn’s ac­cel­er­at­ed ap­proval for can­cer drug af­ter com­pa­ny’s re­quest

Back to the fu­ture: From tar­get-se­lec­tive drug de­sign to AI-en­abled polyphar­ma­col­o­gy

AstraZeneca addresses report that CEO Pascal Soriot plans to depart

‘A new era of growth’: AstraZeneca aims for $80B revenue, 20 new drugs by 2030

Exclusive: Members of Congress buy and sell stocks that would gain from bill banning China biotech companies

Dyne Therapeutics sharpens case for two muscle disease therapies with updated data

FDA approves first two interchangeable biosimilars to Regeneron's blockbuster Eylea

FDA withdraws Helsinn’s accelerated approval for cancer drug after company’s request

Back to the future: From target-selective drug design to AI-enabled polypharmacology